**Supplementary Table 1.** COVID-19 symptom progression. P-Value is calculated using Fisher’s exact test comparing BCG-R (Russia) to BCG-B (Brazil). Placebo data is provided for comparison. Lesion type is compared between two groups using Fisher’s exact test showing a slightly higher probability of pustule formation during the first week in the BCG-Brazil group.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Admission | P | Week 1 | p | | Week 2 | | p | | Week 3 | | p | | Week 6 | | p | |
| Cough | BCG-B 28 (32.9%) BCG-R 37 (37.8%) Placebo 54 (27.7%) | 0.54 | BCG-B 15 (18.1%)  BCG-R 24 (24.5%) Placebo 36 (18.6%) | 0.36 | | BCG-B 10 (12.0%) BCG-R 15 (15.3%) Placebo 21 (10.9%) | | 0.66 | | BCG-B 5 (6.0%)  BCG-R 13 (13.3%)  Placebo 12 (6.2%) | | 0.14 | | BCG-B 5 (6.0%)  BCG-R 10 (10.2%) Placebo 11 (5.7%) | | 0.42 | |
| Fever | BCG-B 1 (1.2%)  BCG-R 2 (2.0%)  Placebo 1 (0.5%) | 1 | BCG-B 0  BCG-R 0 Placebo 2 (1.0%) | - | | BCG-B 0 (0%)  BCG-R 0 (0%) Placebo 0 (0%) | | - | | BCG-B 0 (0%)  BCG-R 0 (0%) Placebo 0 (0%) | | - | | BCG-B 0 (0%)  BCG-R 0 (0%) Placebo 0 (0%) | | - | |
| Chills | BCG-B 5 (5.9%)  BCG-R 2 (2.0%) Placebo 5 (2.6%) | 0.25 | BCG-B 0  BCG-R 1 (1.0%)  Placebo 4 (2.1%) | 1 | | BCG-B 0 BCG-R 0 Placebo 1 (0.5%) | | - | | BCG-B 1 (1.2%)  BCG-R 0 Placebo 1 (0.5%) | | - | | BCG-B 0 (0%)  BCG-R 0 (0%) Placebo 0 (0%) | | - | |
| Fatigue | BCG-B 27 (31.8% BCG-R 29 (29.6%) Placebo 66 (33.8%) | 0.75 | BCG-B 13 (15.7%)  BCG-R 14 (14.3%) Placebo 32 (16.5%) | 0.84 | | BCG-B 12 (14.5%) BCG-R 13 (13.3%) Placebo 20 (10.4%) | | 0.83 | | BCG-B 10 (12.0%)  BCG-R 12 (12.2%)  Placebo 12 (6.2%) | | 1 | | BCG-B 12 (14.5%) BCG-R 7 (7.1%) Placebo 20 (10.4%) | | 0.14 | |
| Coryza | BCG-B 7 (8.2%)  BCG-R 11 (11.2%) Placebo 13 (6.7%) | 0.62 | BCG-B 2 (2.4%)  BCG-R 3 (3.1%)  Placebo 10 (5.2%) | 1 | | BCG-B 5 (6.0%)  BCG-R 4 (4.1%) Placebo 7 (3.6%) | | 0.73 | | BCG-B 4 (4.8%)  BCG-R 3 (3.1%) Placebo 3 (1.6%) | | 0.70 | | BCG-B 3 (3.6%)  BCG-R 1 (1.0%) Placebo 3 (1.6%) | | 0.33 | |
| Nasal Congestion | BCG-B 12 (14.1%) BCG-R 17 (17.3%) Placebo 29 (14.9%) | 0.69 | BCG-B 2 (2.4%)  BCG-R 7 (7.1%) Placebo 14 (7.2% | 0.18 | | BCG-B 3 (3.6%)  BCG-R 3 (3.1%) Placebo 8 (4.1%) | | 1 | | BCG-B 1 (1.2%)  BCG-R 3 (3.1%) Placebo 5 (2.6%) | | 0.62 | | BCG-B 1 (1.2%)  BCG-R 1 (1.0%) Placebo 3 (1.6%) | | 1 | |
| Myalgia | BCG-B 10 (11.8%) BCG-R 17 (17.3%) Placebo 34 (17.4%) | 0.31 | BCG-B 9 (10.8%)  BCG-R 6 (6.1%) Placebo 22 (11.3%) | 0.30 | | BCG-B 4 (4.8%)  BCG-R 3 (3.1%) Placebo 15 (7.8%) | | 0.70 | | BCG-B 5 (6.0%)  BCG-R 6 (6.1%) Placebo 8 (4.1%) | | 1 | | BCG-B 5 (6.0%)  BCG-R 1 (1.0%) Placebo 4 (2.1%) | | 0.095 | |
| Arthralgia | BCG-B 7 (8.2%) BCG-R 9 (9.2%) Placebo 22 (11.3%) | 1 | BCG-B 2 (2.4%)  BCG-R 2 (2.0%) Placebo 12 (6.2%) | 1 | | BCG-B 1 (1.2%)  BCG-R 1 (1.0%) Placebo 6 (3.1%) | | 1 | | BCG-B 1 (1.2%)  BCG-R 2 (2.0%) Placebo 4 (2.1%) | | 1 | | BCG-B 0  BCG-R 2 (2.0%) Placebo 5 (2.6%) | | 1 | |
| Headache | BCG-B 22 (25.9%) BCG-R 19 (19.4%) Placebo 41 (21.0%) | 0.37 | BCG-B 15 (18.1%)  BCG-R 16 (16.3%) Placebo 28 (14.4%) | 0.84 | | BCG-B 1 (1.2%)  BCG-R 1 (1.0%) Placebo 6 (3.1%) | | 1 | | BCG-B 9 (10.8%)  BCG-R 11 (11.2%) Placebo 15 (7.8%) | | 1 | | BCG-B 10 (12.0%) BCG-R 10 (10.2%) Placebo 11 (5.7%) | | 0.81 | |
| Sore throat | BCG-B 11 (12.9%) BCG-R 10 (10.2%) Placebo 26 (13.3%) | 0.64 | BCG-B 4 (4.8%)  BCG-R 5 (5.1%) Placebo 8 (4.1%) | 1 | | BCG-B 2 (2.4%)  BCG-R 3 (3.1%) Placebo 5 (2.6%) | | 1 | | BCG-B 2 (2.4%)  BCG-R 3 (3.1%) Placebo 8 (4.1%) | | 1 | | BCG-B 0  BCG-R 0 Placebo 3 (1.6%) | | - | |
| Anosmia | BCG-B 34 (40.0%) BCG-R 49 (50.0%) Placebo 87 (44.6%) | 0.18 | BCG-B 22 (26.5%)  BCG-R 26 (26.5%) Placebo 76 (39.2%) | 1 | | BCG-B 13 (15.7%) BCG-R 25 (25.5%) Placebo 55 (28.5%) | | 0.14 | | BCG-B 13 (15.7%)  BCG-R 15 (15.3%) Placebo 43 (22.3%) | | 1 | | BCG-B 7 (8.4%)  BCG-R 10 (10.2%) Placebo 35 (18.1%) | | 0.80 | |
| Ageusia | BCG-B 30 (35.3%) BCG-R 40 (40.8%) Placebo 69 (35.4) | 0.45 | BCG-B 19 (22.9%)  BCG-R 23 (23.5%) Placebo 59 (30.4%) | 1 | | BCG-B 9 (10.8%) BCG-R 21 (21.4%) Placebo 44 (22.8%) | | 0.071 | | BCG-B 11 (13.3%)  BCG-R 15 (15.3%) Placebo 34 (17.6%) | | 0.83 | | BCG-B 5 (6.0%)  BCG-R 9 (9.2%) Placebo 25 (13.0%) | | 0.58 | |
| Nausea | BCG-B 5 (5.9%) BCG-R 10 (10.2%) Placebo 16 (8.2%) | 0.42 | BCG-B 3 (3.6%)  BCG-R 1 (1.0%) Placebo 5 (2.6%) | 0.33 | | BCG-B 0 BCG-R 1 (1.0%) Placebo 2 (1.0%) | | 1 | | BCG-B 1  BCG-R 0 Placebo 1 | | 1 | | BCG-B 1  BCG-R 1 Placebo 0 | | 1 | |
| Vomiting | BCG-B 1 (1.2%) BCG-R 0 Placebo 1 (0.5%) | 0.46 | BCG-B 1  BCG-R 0 Placebo 0 | - | | BCG-B 0 (0%)  BCG-R 0 (0%) Placebo 0 (0%) | | - | | BCG-B 0  BCG-R 1 Placebo 0 | | - | | BCG-B 0 (0%)  BCG-R 0 (0%) Placebo 0 (0%) | | - | |
| Diarrhea | BCG-B 8 (9.4%) BCG-R 6 (6.1%) Placebo 10 (5.1%) | 0.42 | BCG-B 2 (2.4%)  BCG-R 1 (1.0%) Placebo 6 (3.1%) | 0.59 | | BCG-B 2 (2.4%)  BCG-R 2 (2.0%) Placebo 2 (1.0%) | | 1 | | BCG-B 1  BCG-R 1 Placebo 1 | | 1 | | BCG-B 1  BCG-R 1 Placebo 0 | | 1 | |
| Chest pain | BCG-B 6 (7.1%) BCG-R 10 (10.2%) Placebo 11 (5.6%) | 0.60 | BCG-B 2 (2.4%)  BCG-R 3 (3.1%) Placebo 4 (2.1%) | 1 | | BCG-B 1 (1.2%)  BCG-R 0 Placebo 3 (1.6%) | | 1 | | BCG-B 2 (2.4%)  BCG-R 0 Placebo 1 (0.5%) | | 1 | | BCG-B 1 (1.2%)  BCG-R 1 (1.0%) Placebo 2 (1.0%) | | 1 | |
| Dyspnea | BCG-B 11 (12.9%) BCG-R 13 (13.3%) Placebo 17 (8.7%) | 1 | BCG-B 4 (4.8%)  BCG-R 9 (9.2%) Placebo 10 (5.2%) | 0.39 | | BCG-B 2 (2.4%)  BCG-R 4 (4.1%) Placebo 7 (3.6%) | | 0.69 | | BCG-B 1 (1.2%)  BCG-R 4 (4.1%) Placebo 6 (3.1%) | | 0.38 | | BCG-B 4 (4.8%)  BCG-R 1 (1.0%) Placebo 3 (1.6%) | | 0.18 | |
| Somnolence | BCG-B 9 (10.6%) BCG-R 13 (13.3%) Placebo 19 (9.7%) | 0.65 | BCG-B 2 (2.4%)  BCG-R 8 (8.2%) Placebo 7 (3.6%) | 0.112 | | BCG-B 3 (3.6%)  BCG-R 3 (3.1%) Placebo 6 (3.1%) | | 1 | | BCG-B 1 (1.2%)  BCG-R 2 (2.0%) Placebo 3 (1.6%) | | 1 | | BCG-B 3 (3.6%)  BCG-R 0 Placebo 4 (2.1%) | | 0.095 | |
| Mental confusion | BCG-B 4 (4.7%)  BCG-R 2 (2.0%) Placebo 3 (1.5%) | 0.42 | BCG-B 0  BCG-R 2 (2.0%)  Placebo 1 (0.5%) | 0.50 | | BCG-B 0 BCG-R 1 (1.0%) Placebo 2 (1.0%) | | 1 | | BCG-B 1 (1.2%)  BCG-R 0 Placebo 1 (0.5%) | | 1 | | BCG-B 0  BCG-R 1 (1.0%) Placebo 3 (1.6%) | | 1 | |
| Median number of symptoms | BCG-B 2  BCG-R 2 Placebo 2 | 0.63 | BCG-B 1  BCG-R 1  Placebo 1 | 0.51 | | BCG-B 1  BCG-R 0  Placebo 1 | | 0.15 | | BCG-B 0  BCG-R 0  Placebo 0 | | 0.31 | | BCG-B 0  BCG-R 0  Placebo 0 | | 0.37 | |
| Erythema | | | BCG-B 72 (86.7%)  BCG-R 80 (81.6%) Placebo 2 (1.0%) | 0.42 | BCG-B 65 (78.3%) BCG-R 82 (83.7%) Placebo 3 (1.6%) | | 0.45 | | BCG-B 57 (68.7%)  BCG-R 72 (73.5%) Placebo 3 (1.6%) | | 0.52 | | BCG-B 45 (45.8%) BCG-R 63 (64.3%) Placebo 0 | | 0.18 | |
| Erythema size | | | B 11.4 ± 6.8  I 10.4 ± 5.4  P 5.0 ± 0 |  | 10.3 ± 3.8  10.5 ± 4.3  2.5 ± 0.7 | |  | | 9.0 ± 2.6  10.6 ± 5.7  3.0 ± 1.0 | |  | | 7.1 ± 3.0  7.2 ± 3.1 | |  | |
| Papule | | | BCG-B 50 (60.2%)  BCG-R 61 (62.2%) Placebo 1 (0.5%) | 0.88 | BCG-B 32 (38.6%) BCG-R 44 (44.9%) Placebo 4 (2.1%) | | 0.45 | | BCG-B 28 (33.7%)  BCG-R 39 (39.8%)  Placebo 1 (0.5%) | | 0.44 | | BCG-B 16 (19.3%) BCG-R 16 (16.3%) Placebo 1 (0.5%) | | 0.70 | |
| Papule size | | | 11.1 ± 6.6  9.8 ± 5.4  5.0 |  | 9.6 ± 3.3  8.8 ± 2.7  4.0 ± 1.4 | |  | | 8.9 ± 2.9  9.9 ± 4.8  4.0 | |  | | 6.3 ± 2.5  6.7 ± 4.1  3.0 | |  | |
| Pustule | | | BCG-B 11 (13.3%)  BCG-R 5 (5.1%)  Placebo 1 (0.5%) | 0.067 | BCG-B 13 (15.7%) BCG-R 21 (21.4%) Placebo 0 | | 0.35 | | BCG-B 5 (6.0%)  BCG-R 8 (8.2%) Placebo 0 | | 0.77 | | BCG-B 4 (4.8%)  BCG-R 4 (4.1%) Placebo 0 | | 1 | |
| Pustule size | | | 13.3 ± 7.7  11.3 ± 2.5  2.5 |  | 9.9 ± 4.2  12.6 ± 5.2 | |  | | 11.5 ± 4.2  8.8 ± 1.4 | |  | | 5.5 ± 3.9  6.5 ± 1.9 | |  | |
| Pain | | | BCG-B 6 (7.2%)  BCG-R 9 (9.2%)  Placebo 0 | 0.80 | BCG-B 9 (10.8%) BCG-R 12 (12.2%) Placebo 1 (0.5%) | | 0.82 | | BCG-B 5 (6.0%)  BCG-R 7 (7.1%) Placebo 0 | | 1 | | BCG-B 3 (3.6%)  BCG-R 1 (1.0%) Placebo 0 | | 0.33 | |
| Pain size | | | 6.8 ± 6.6  13.8 ± 8.2 |  | 11.3 ± 6.6  12.7 ± 5.4 | |  | | 7.6 ± 3.4  13.2 ± 5.8 | |  | | 8.3 ± 2.9  5.0 | |  | |
| Itching | | | BCG-B 11 (13.3%)  BCG-R 13 (13.3%) Placebo 0 | 1 | BCG-B 2 (2.4%)  BCG-R 9 (9.2%) Placebo 0 | | 0.067 | | BCG-B 6 (7.2%)  BCG-R 7 (7.1%) Placebo 0 | | 1 | | BCG-B 2 (2.4%)  BCG-R 5 (5.1%) Placebo 0 | | 0.46 | |
| Itching size | | | 10.9 ± 5.6  9.9 ± 6.1 |  | 10.0 ± 0  10.4 ± 0.9 | |  | | 10.5 ± 1.0  11.8 ± 7.4 | |  | | 8.0 ± 0  6.6 ± 1.1 | |  | |
| Ulcer | | | BCG-B 0 (0%)  BCG-R 0 (0%) Placebo 0 (0%) | - | BCG-B 1 (1.2%)  BCG-R 3 (3.1%) Placebo 0 | | 0.63 | | BCG-B 1 (1.2%)  BCG-R 6 (6.1%) Placebo 0 | | 0.13 | | BCG-B 0  BCG-R 7 (7.1%) Placebo 0 | | 0.016 | |
| Ulcer size | | |  |  | 10.0  12.5 ± 3.5 | |  | | 8.0  8.8 ± 2.5 | |  | | -  7.4 ± 1.4 | |  | |
| Crust | | | BCG-B 3 (3.6%)  BCG-R 1 (1.0%)  Placebo 0 | 0.33 | BCG-B 13 (15.7%) BCG-R 8 (8.2%) Placebo 0 | | 0.16 | | BCG-B 8 (9.6%)  BCG-R 15 (15.3%)  Placebo 0 | | 0.27 | | BCG-B 15 (18.1%) BCG-R 23 (23.5%) Placebo 0 | | 0.46 | |
| Crust size | | |  |  | 9.5 ± 2.2  9.7 ± 2.4 | |  | | 9.6 ± 1.1  9.9 ± 1.7 | |  | | 7.0 ± 2.4  6.7 ± 2.1 | |  | |
| Scar | | | BCG-B 0 (0%)  BCG-R 0 (0%) Placebo 0 (0%) | - | BCG-B 1 (1.2%)  BCG-R 1 (1.0%) Placebo 1 (0.5)% | | 1 | | BCG-B 3 (3.6%)  BCG-R 3 (3.1%) Placebo 3 (1.6%) | | 1 | | BCG-B 17 (20.5%) BCG-R 19 (19.4%) Placebo 1 (0.5%) | | 0.85 | |
| Scar size | | |  |  | 12  10  3 | |  | | 6.7 ± 4.0  16.0 ± 12.7  4.0 ± 1.4 | |  | | 6.8 ± 2.8  6.4 ± 1.8  5 | |  | |
| Peeling | | | BCG-B 1 (1.2)  BCG-R 2 (2.0%) Placebo 0 | 1 | BCG-B 9 (10.8%) BCG-R 7 (7.1%) Placebo 0 | | 0.44 | | BCG-B 7 (8.4%)  BCG-R 13 (13.3%) Placebo 0 | | 0.35 | | BCG-B 13 (15.7%) BCG-R 25 (25.5%) Placebo 0 | | 0.14 | |
| Peeling size | | | 15  12 |  | 10.3 ± 2.2  11.3 ± 2.2 | |  | | 9.4 ± 3.0  9.8 ± 5.8 | |  | | 7.7 ± 2.3  7.8 ± 3.1 | |  | |
| Vesicle | | | BCG-B 0 (0%)  BCG-R 0 (0%) Placebo 0 (0%) | - | BCG-B 0 (0%)  BCG-R 0 (0%) Placebo 0 (0%) | | - | | BCG-B 0 (0%)  BCG-R 0 (0%) Placebo 0 (0%) | | - | | BCG-B 0 (0%)  BCG-R 0 (0%) Placebo 0 (0%) | | - | |
| Lymphadenopathy | | | BCG-B 0 (0%)  BCG-R 0 (0%) Placebo 0 (0%) | - | BCG-B 0 (0%)  BCG-R 0 (0%) Placebo 0 (0%) | | - | | BCG-B 0 (0%)  BCG-R 0 (0%) Placebo 0 (0%) | | - | | BCG-B 0 (0%)  BCG-R 0 (0%) Placebo 0 (0%) | | - | |
| Lesion size overall | | | BCG-B 11.0 ± 6.6  BCG-R 10.3 ± 5.5 | 0.26 | BCG-B 10.2 ± 3.7  BCG-R 10.4 ± 4.3 | | 0.80 | | BCG-B 8.8 ± 3.1  BCG-R 10.4 ± 5.4 | | 0.18 | | BCG-B 6.6 ± 2.8  BCG-R 6.9 ± 2.9 | | 0.55 | |